Clinical Trial Update: Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ixazomib citrate and lenalidomide after stem cell transplant in newly diagnosed multiple myeloma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-28